High-throughput screening for TLR3-IFN regulatory factor 3 signaling pathway modulators identifies several antipsychotic drugs as TLR inhibitors

Journal of Immunology

Volumn 184, Issue 10, 2010, Pages 5768-5776

  Zhu, Jianzhong ^a,b   Smith, Kevin ^c   Hsieh, Paishiun N ^a,b   Mburu, Yvonne K ^b   Chattopadhyay, Saurabh ^c   Sen, Ganes C ^c   Sarkar, Saumendra N ^a,b,c  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,3,6,7 TETRAHYDRO 1' METHYL 5 [[2' METHYL 4' (5 METHYL 1,2,4 OXADIAZOL 3 YL) 4 BIPHENYLYL]CARBONYL]SPIRO[FURO[2,3 F]INDOLE 3,4' PIPERIDINE]; AMLODIPINE BESYLATE; DOUBLE STRANDED RNA; FLUPHENAZINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERFERON REGULATORY FACTOR 3; LUCIFERASE; NEUROLEPTIC AGENT; PHOSPHATIDYLINOSITOL 3 KINASE; SERTRALINE; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 8; TRIFLUOPERAZINE; 2 MORPHOLINO 8 PHENYLCHROMONE; 2-(4-MORPHOLINYL)-8-PHENYL-4H-1-BENZOPYRAN-4-ONE; CHROMONE DERIVATIVE; ISG56 PROTEIN, HUMAN; MORPHOLINE DERIVATIVE; TLR3 PROTEIN, HUMAN; TRANSCRIPTION FACTOR;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL STRAIN HEK293; CONTROLLED STUDY; DRUG MECHANISM; ENZYME INDUCTION; GENE INDUCTION; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; INNATE IMMUNITY; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN RNA BINDING; SIGNAL TRANSDUCTION; BIOSYNTHESIS; CELL CLONE; CELL CULTURE; CELL LINE; DRUG ANTAGONISM; DRUG EFFECT; IMMUNOLOGY; METHODOLOGY; PHYSIOLOGY; TUMOR CELL LINE;

ANTIPSYCHOTIC AGENTS; CELL LINE; CELL LINE, TUMOR; CELLS, CULTURED; CHROMONES; CLONE CELLS; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; INTERFERON REGULATORY FACTOR-3; MORPHOLINES; RNA, DOUBLE-STRANDED; SERTRALINE; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTOR 3; TRANSCRIPTION FACTORS; TRIFLUOPERAZINE;

EID: 77954725890     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.0903559     Document Type: Article

References (49)

1. Akira, S., S. Uematsu, and O. Takeuchi. 2006. Pathogen recognition and innate immunity. Cell 124: 783-801.
2. Alexopoulou, L., A. C. Holt, R. Medzhitov, and R. A. Flavell. 2001. Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature 413: 732-738. (Pubitemid 33009951)
3. Kato, H., O. Takeuchi, S. Sato, M. Yoneyama, M. Yamamoto, K. Matsui, S. Uematsu, A. Jung, T. Kawai, K. J. Ishii, et al. 2006. Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses. Nature 441: 101-105.
4. Yoneyama, M., M. Kikuchi, T. Natsukawa, N. Shinobu, T. Imaizumi, M. Miyagishi, K. Taira, S. Akira, and T. Fujita. 2004. The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate antiviral responses. Nat. Immunol. 5: 730-737.
5. Sen, G. C., and S. N. Sarkar. 2005. Transcriptional signaling by double-stranded RNA: role of TLR3. Cytokine Growth Factor Rev. 16: 1-14.
6. Kawai, T., and S. Akira. 2006. Innate immune recognition of viral infection. Nat. Immunol. 7: 131-137.
7. Kumar, A., J. Zhang, and F. S. Yu. 2006. Toll-like receptor 3 agonist poly(I:C)-induced antiviral response in human corneal epithelial cells. Immunology 117: 11-21.
8. Lafon, M., F. Megret, M. Lafage, and C. Prehaud. 2006. The innate immune facet of brain: human neurons express TLR-3 and sense viral dsRNA. J. Mol. Neurosci. 29: 185-194.
9. Yamamoto, M., S. Sato, K. Mori, K. Hoshino, O. Takeuchi, K. Takeda, and S. Akira. 2002. Cutting edge: a novel Toll/IL-1 receptor domain-containing adapter that preferentially activates the IFN-beta promoter in the Toll-like receptor signaling. J. Immunol. 169: 6668-6672.
10. Oganesyan, G., S. K. Saha, B. Guo, J. Q. He, A. Shahangian, B. Zarnegar, A. Perry, and G. Cheng. 2006. Critical role of TRAF3 in the Toll-like receptor-dependent and -independent antiviral response. Nature 439: 208-211. (Pubitemid 43083142)
11. Shim, J. H., C. Xiao, A. E. Paschal, S. T. Bailey, P. Rao, M. S. Hayden, K. Y. Lee, C. Bussey, M. Steckel, N. Tanaka, et al. 2005. TAK1, but not TAB1 or TAB2, plays an essential role in multiple signaling pathways in vivo. Genes Dev. 19: 2668-2681.
12. Au, W. C., P. A. Moore, W. Lowther, Y. T. Juang, and P. M. Pitha. 1995. Identification of a member of the interferon regulatory factor family that binds to the interferon-stimulated response element and activates expression of interferon-induced genes. Proc. Natl. Acad. Sci. USA 92: 11657-11661.
13. Peters, K. L., H. L. Smith, G. R. Stark, and G. C. Sen. 2002. IRF-3-dependent, NFkappa B- and JNK-independent activation of the 561 and IFN-beta genes in response to double-stranded RNA. Proc. Natl. Acad. Sci. USA 99: 6322-6327.
14. Sharma, S., B. R. tenOever, N. Grandvaux, G. P. Zhou, R. Lin, and J. Hiscott. 2003. Triggering the interferon antiviral response through an IKK-related pathway. Science 300: 1148-1151.
15. Fitzgerald, K. A., S. M. McWhirter, K. L. Faia, D. C. Rowe, E. Latz, D. T. Golenbock, A. J. Coyle, S. M. Liao, and T. Maniatis. 2003. IKKepsilon and TBK1 are essential components of the IRF3 signaling pathway. Nat. Immunol. 4: 491-496.
16. Karin, M., T. Lawrence, and V. Nizet. 2006. Innate immunity gone awry: linking microbial infections to chronic inflammation and cancer. Cell 124: 823-835.
17. Marsh, B. J., and M. P. Stenzel-Poore. 2008. Toll-like receptors: novel pharmacological targets for the treatment of neurological diseases. Curr. Opin. Pharmacol. 8: 8-13.
18. Pashine, A., N. M. Valiante, and J. B. Ulmer. 2005. Targeting the innate immune response with improved vaccine adjuvants. Nat. Med. 11(4 Suppl)S63-S68.
19. O'Neill, L. A. 2003. Therapeutic targeting of Toll-like receptors for inflammatory and infectious diseases. Curr. Opin. Pharmacol. 3: 396-403.
20. Wang, T., T. Town, L. Alexopoulou, J. F. Anderson, E. Fikrig, and R. A. Flavell. 2004. Toll-like receptor 3 mediates West Nile virus entry into the brain causing lethal encephalitis. Nat. Med. 10: 1366-1373.
21. Gowen, B. B., J. D. Hoopes, M. H. Wong, K. H. Jung, K. C. Isakson, L. Alexopoulou, R. A. Flavell, and R. W. Sidwell. 2006. TLR3 deletion limits mortality and disease severity due to Phlebovirus infection. J. Immunol. 177: 6301-6307.
22. Hutchens, M., K. E. Luker, P. Sottile, J. Sonstein, N. W. Lukacs, G. Núñez, J. L. Curtis, and G. D. Luker. 2008. TLR3 increases disease morbidity and mortality from vaccinia infection. J. Immunol. 180: 483-491.
23. Lee, H. K., S. J. Brown, H. Rosen, and P. S. Tobias. 2007. Application of beta-lactamase enzyme complementation to the high-throughput screening of toll-like receptor signaling inhibitors. Mol. Pharmacol. 72: 868-875.
24. Sarkar, S. N., K. L. Peters, C. P. Elco, S. Sakamoto, S. Pal, and G. C. Sen. 2004. Novel roles of TLR3 tyrosine phosphorylation and PI3 kinase in double-stranded RNA signaling. Nat. Struct. Mol. Biol. 11: 1060-1067.
25. Wang, J., L. Xi, J. L. Hunt, W. Gooding, T. L. Whiteside, Z. Chen, T. E. Godfrey, and R. L. Ferris. 2004. Expression pattern of chemokine receptor 6 (CCR6) and CCR7 in squamous cell carcinoma of the head and neck identifies a novel metastatic phenotype. Cancer Res. 64: 1861-1866.
26. Malo, N., J. A. Hanley, S. Cerquozzi, J. Pelletier, and R. Nadon. 2006. Statistical practice in high-throughput screening data analysis. Nat. Biotechnol. 24: 167-175.
27. Zhang, J. H., T. D. Chung, and K. R. Oldenburg. 1999. A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays. J. Biomol. Screen. 4: 67-73.
28. Sarkar, S. N., and G. C. Sen. 2004. Novel functions of proteins encoded by viral stress-inducible genes. Pharmacol. Ther. 103: 245-259.
29. Geiss, G., G. Jin, J. Guo, R. Bumgarner, M. G. Katze, and G. C. Sen. 2001. A comprehensive view of regulation of gene expression by double-stranded RNA-mediated cell signaling. J. Biol. Chem. 276: 30178-30182.
30. Takeuchi, O., and S. Akira. 2008. MDA5/RIG-I and virus recognition. Curr. Opin. Immunol. 20: 17-22.
31. Peters, K., S. Chattopadhyay, and G. C. Sen. 2008. IRF-3 activation by Sendai virus infection is required for cellular apoptosis and avoidance of persistence. J. Virol. 82: 3500-3508. (Pubitemid 351429925)
32. Grandvaux, N., M. J. Servant, B. tenOever, G. C. Sen, S. Balachandran, G. N. Barber, R. Lin, and J. Hiscott. 2002. Transcriptional profiling of interferon regulatory factor 3 target genes: direct involvement in the regulation of interferon-stimulated genes. J. Virol. 76: 5532-5539.
33. Maniatis, T., J. V. Falvo, T. H. Kim, T. K. Kim, C. H. Lin, B. S. Parekh, and M. G. Wathelet. 1998. Structure and function of the interferon-beta enhanceosome. Cold Spring Harb. Symp. Quant. Biol. 63: 609-620.
34. Werner, S. L., D. Barken, and A. Hoffmann. 2005. Stimulus specificity of gene expression programs determined by temporal control of IKK activity. Science 309: 1857-1861.
35. Roumestan, C., A. Michel, F. Bichon, K. Portet, M. Detoc, C. Henriquet, D. Jaffuel, and M. Mathieu. 2007. Anti-inflammatory properties of desipramine and fluoxetine. Respir. Res. 8: 35.
36. Taler, M., I. Gil-Ad, L. Lomnitski, I. Korov, E. Baharav, M. Bar, A. Zolokov, and A. Weizman. 2007. Immunomodulatory effect of selective serotonin reuptake inhibitors (SSRIs) on human T lymphocyte function and gene expression. Eur. Neuropsychopharmacol. 17: 774-780.
37. Xia, Z., J. W. DePierre, and L. Nässberger. 1996. Tricyclic antidepressants inhibit IL-6, IL-1 beta and TNF-alpha release in human blood monocytes and IL-2 and interferon-gamma in T cells. Immunopharmacology 34: 27-37.
38. Ruse, M., and U. G. Knaus. 2006. New players in TLR-mediated innate immunity: PI3K and small Rho GTPases. Immunol. Res. 34: 33-48.
39. Guiducci, C., C. Ghirelli, M. A. Marloie-Provost, T. Matray, R. L. Coffman, Y. J. Liu, F. J. Barrat, and V. Soumelis. 2008. PI3K is critical for the nuclear translocation of IRF-7 and type I IFN production by human plasmacytoid predendritic cells in response to TLR activation. J. Exp. Med. 205: 315-322.
40. Rajagopal, R., A. S. Waller, J. D. Mendoza, and P. D. Wightman. 2008. The covalent modification and regulation of TLR8 in HEK-293 cells stimulated with imidazoquinoline agonists. Biochem. J. 409: 275-287.
41. Doyle, S. L., C. A. Jefferies, C. Feighery, and L. A. O'Neill. 2007. Signaling by Toll-like receptors 8 and 9 requires Bruton's tyrosine kinase. J. Biol. Chem. 282: 36953-36960.
42. Guha, M., and N. Mackman. 2002. The phosphatidylinositol 3-kinase-Akt pathway limits lipopolysaccharide activation of signaling pathways and expression of inflammatory mediators in human monocytic cells. J. Biol. Chem. 277: 32124-32132.
43. Laird, M. H., S. H. Rhee, D. J. Perkins, A. E. Medvedev, W. Piao, M. J. Fenton, and S. N. Vogel. 2009. TLR4/MyD88/PI3K interactions regulate TLR4 signaling. J. Leukoc. Biol. 85: 966-977.
44. Schabbauer, G., J. Luyendyk, K. Crozat, Z. Jiang, N. Mackman, S. Bahram, and P. Georgel. 2008. TLR4/CD14-mediated PI3K activation is an essential component of interferon-dependent VSV resistance in macrophages. Mol. Immunol. 45: 2790-2796.
45. Tsukamoto, K., K. Hazeki, M. Hoshi, K. Nigorikawa, N. Inoue, T. Sasaki, and O. Hazeki. 2008. Critical roles of the p110 beta subtype of phosphoinositide 3-kinase in lipopolysaccharide-induced Akt activation and negative regulation of nitrite production in RAW 264.7 cells. J. Immunol. 180: 2054-2061.
46. Eskan, M. A., B. G. Rose, M. R. Benakanakere, M. J. Lee, and D. F. Kinane. 2008. Sphingosine 1-phosphate 1 and TLR4 mediate IFN-beta expression in human gingival epithelial cells. J. Immunol. 180: 1818-1825.
47. Zhou, Z., J. Zhen, N. K. Karpowich, R. M. Goetz, C. J. Law, M. E. Reith, and D. N. Wang. 2007. LeuT-desipramine structure reveals how antidepressants block neurotransmitter reuptake. Science 317: 1390-1393. (Pubitemid 47417479)
48. Zhou, Z., J. Zhen, N. K. Karpowich, C. J. Law, M. E. Reith, and D. N. Wang. 2009. Antidepressant specificity of serotonin transporter suggested by three LeuT-SSRI structures. Nat. Struct. Mol. Biol. 16: 652-657.
49. Itoh, K., A. Watanabe, K. Funami, T. Seya, and M. Matsumoto. 2008. The clathrin-mediated endocytic pathway participates in dsRNA-induced IFN-beta production. J. Immunol. 181: 5522-5529.